Potential Promise for Cancer Patients

Delivering Therapy Where it Matters

Investigation of Potential Promise to Cancer Therapy

TIGeR-PaC Phase 3 Clinical Trial Now Enrolling

Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.

A promising potential new option for targeted treatment is being studied in a clinical trial intended to investigate its effect on reducing the chances of the cancer spreading and extending survival, while improving quality of life.

Introducing Trans-Arterial Micro-Perfusion (TAMP™)

TAMP therapy utilizes RenovoRx’s proprietary platform technology designed to deliver well-established chemotherapeutic agents for localized treatment of solid cancer tumors, to increase survival and improve quality of life. This drug delivery technology enables TAMP to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy.

The TIGeR-PaC clinical trial is a randomized study of intra-arterial gemcitabine utilizing the TAMP procedure and is enrolling newly-diagnosed, unresectable locally advanced pancreatic cancer patients. In one clinical study gemcitabine delivered directly via the pancreatic arteries using TAMP was associated with more than half the patients living over two years.*

* Agah, Ramtin, Rosemurgy, Alexander. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma, Journal of Pancreatic Cancer; Vol. 3, issue 1.

In The News

RenovoRx Announces Sixth U.S. Patent

TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in the U.S. and Europe Los Altos, CA, June 9, 2020 – RenovoRx, an innovator in targeted cancer…
Read More

* Individual results may vary.